New to HBW Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
cCAM Biotherapeutics Ltd.
Division of Merck & Co. Inc.
ccam-bio.com
Latest From cCAM Biotherapeutics Ltd.
Finance Watch: VC Deals Keep Up Fast Pace With $1.1bn In Less Than Three Weeks
Finance Watch has noted $1.1bn worth of venture capital deals so far in 2019. Meanwhile, public offerings continue to be muted by the US government shutdown, though Revance and others sold shares. Also, Five Prime and others reveal layoffs and strategic shifts.
Biopharma Quarterly Dealmaking Statistics, Q3 2015
Biopharma financing totaled $9.7 billion, almost half from follow-on public offerings; there was big consolidation in the generics and health services industries. AstraZeneca signed a dozen partnerships, many of which focused on oncology.
Company Information
- Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
- Therapeutic Areas
- Cancer
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
Middle East
-
Israel
-
Israel
-
Middle East
- Parent & Subsidiaries
- Merck & Co. Inc.
- Senior Management
-
Tehila Ben-Moshe, PhD, VP, R&D & COO
Gal Markel, MD, PhD, CSO
Pini Orbach, PhD, Chmn. - Contact Info
-
cCAM Biotherapeutics Ltd.
Phone: 4 9534651
Misgav Industrial Park
P.O. Box 79 Misgav, 2017400
Israel
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
cCAM Biotherapeutics Ltd.
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice